Price
CHART BY
Frequently asked questions
What is Altimmune's market capitalization?
The market capitalization of Altimmune is $628.29M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Altimmune?
Altimmune's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.789. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Altimmune's stock?
Currently, 9 analysts cover Altimmune's stock, with a consensus target price of $17.13. Analyst ratings provide insights into the stock's expected performance.
What is Altimmune's revenue over the trailing twelve months?
Over the trailing twelve months, Altimmune reported a revenue of $31.00K.
What is the EBITDA for Altimmune?
Altimmune's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$99.33M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Altimmune?
Altimmune has a free cash flow of -$76.26M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Altimmune have, and what sector and industry does it belong to?
Altimmune employs approximately 57 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Altimmune's shares?
The free float of Altimmune is 183.69M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $628.29M
- EPS (TTM)
- -$0.789
- Free Float
- 183.69M
- Revenue (TTM)
- $31.00K
- EBITDA (TTM)
- -$99.33M
- Free Cashflow (TTM)
- -$76.26M
Pricing
- 1D span
- $3.209$3.426
- 52W span
- $2.565$6.43
Analyst Ratings
The price target is $17.13 and the stock is covered by 9 analysts.
Buy
8
Hold
1
Sell
0
Information
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
- Employees
- 57
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ALT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet